Birdwatch Archive

Birdwatch Note

2023-12-03 14:04:27 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING

インフルエンザワクチンにｍRNAが混入される訳では無い。 インフルエンザ対応のmRNAワクチンが作られ、供給される予定である。 https://www.pfizer.com/news/press-release/press-release-detail/pfizer-initiates-phase-3-study-mrna-based-influenza-vaccine 従来の細胞増殖を利用したワクチンは、製造に約半年かかっていた。 流行株の事前予測の難しさと、実験室と外界とで異なる変異をしてしまう可能性があった。 mRNAワクチンは短期間で量産できる為、これらの問題によるミスマッチを回避できるという。 https://www.pfizer.com/news/articles/what_does_mrna_mean_for_the_flu_vaccine なお従来のワクチンでウィルスの養殖に使う細胞は、彼女がmRNAワクチンを糾弾する為に引き合いに出した『蛾細胞』を利用するタイプもある。 https://www.respectfulinsolence.com/2022/07/22/novavax-and-moth-cells-the-latest-antivax-fear-mongering/ @gorskonより

Written by 8C120F8B617DBAC9E4696DE6F24E78952C3CAB0AAA8B11A719AE451FCC3B40DD
Participant Details

Original Tweet

Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1731201803176628555

Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.

All Information

  • ID - 1731313449932857375
  • noteId - 1731313449932857375
  • participantId -
  • noteAuthorParticipantId - 8C120F8B617DBAC9E4696DE6F24E78952C3CAB0AAA8B11A719AE451FCC3B40DD Participant Details
  • createdAtMillis - 1701612267370
  • tweetId - 1731201803176628555
  • classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
  • believable -
  • harmful -
  • validationDifficulty -
  • misleadingOther - 0
  • misleadingFactualError - 0
  • misleadingManipulatedMedia - 0
  • misleadingOutdatedInformation - 0
  • misleadingMissingImportantContext - 1
  • misleadingUnverifiedClaimAsFact - 0
  • misleadingSatire - 0
  • notMisleadingOther - 0
  • notMisleadingFactuallyCorrect - 0
  • notMisleadingOutdatedButNotWhenWritten - 0
  • notMisleadingClearlySatire - 0
  • notMisleadingPersonalOpinion - 0
  • trustworthySources - 1
  • summary
    • インフルエンザワクチンにｍRNAが混入される訳では無い。 インフルエンザ対応のmRNAワクチンが作られ、供給される予定である。 https://www.pfizer.com/news/press-release/press-release-detail/pfizer-initiates-phase-3-study-mrna-based-influenza-vaccine 従来の細胞増殖を利用したワクチンは、製造に約半年かかっていた。 流行株の事前予測の難しさと、実験室と外界とで異なる変異をしてしまう可能性があった。 mRNAワクチンは短期間で量産できる為、これらの問題によるミスマッチを回避できるという。 https://www.pfizer.com/news/articles/what_does_mrna_mean_for_the_flu_vaccine なお従来のワクチンでウィルスの養殖に使う細胞は、彼女がmRNAワクチンを糾弾する為に引き合いに出した『蛾細胞』を利用するタイプもある。 https://www.respectfulinsolence.com/2022/07/22/novavax-and-moth-cells-the-latest-antivax-fear-mongering/ @gorskonより

Note Status History

createdAt timestampMillisOfFirstNonNMRStatus firstNonNMRStatus timestampMillisOfCurrentStatus currentStatus timestampMillisOfLatestNonNMRStatus mostRecentNonNMRStatus participantId
2023-12-03 14:04:27 UTC
(1701612267370)		 2023-12-04 01:03:31 UTC
(1701651811909)		 CURRENTLY_RATED_HELPFUL 2023-12-05 03:33:02 UTC
(1701747182239)		 NEEDS_MORE_RATINGS 2023-12-04 01:03:31 UTC
(1701651811909)		 CURRENTLY_RATED_HELPFUL

Note Ratings

rated at rated by
2023-12-03 18:09:26 -0600 Rating Details
2023-12-03 17:40:06 -0600 Rating Details
2023-12-03 17:11:58 -0600 Rating Details
2023-12-03 16:42:23 -0600 Rating Details
2023-12-03 15:41:16 -0600 Rating Details
2023-12-03 14:51:09 -0600 Rating Details
2023-12-03 14:27:39 -0600 Rating Details
2023-12-03 13:37:19 -0600 Rating Details
2023-12-03 12:26:11 -0600 Rating Details
2023-12-03 11:04:08 -0600 Rating Details
2023-12-03 10:14:44 -0600 Rating Details
2023-12-03 09:37:32 -0600 Rating Details
2023-12-03 09:35:44 -0600 Rating Details
2023-12-03 09:16:10 -0600 Rating Details
2023-12-03 09:10:56 -0600 Rating Details
2023-12-03 09:10:02 -0600 Rating Details
2023-12-03 09:02:25 -0600 Rating Details
2023-12-03 08:44:47 -0600 Rating Details
2023-12-03 08:26:16 -0600 Rating Details
2023-12-03 08:25:37 -0600 Rating Details
2023-12-03 08:23:07 -0600 Rating Details
2023-12-03 08:21:23 -0600 Rating Details
2023-12-04 16:39:32 -0600 Rating Details
2023-12-04 03:30:07 -0600 Rating Details
2023-12-04 02:23:18 -0600 Rating Details
2023-12-04 00:37:44 -0600 Rating Details
2023-12-03 19:47:48 -0600 Rating Details
2023-12-03 19:12:40 -0600 Rating Details
2023-12-03 18:17:00 -0600 Rating Details
2023-12-03 17:22:29 -0600 Rating Details
2023-12-03 17:20:01 -0600 Rating Details
2023-12-03 16:44:40 -0600 Rating Details
2023-12-03 16:01:29 -0600 Rating Details
2023-12-03 15:36:07 -0600 Rating Details
2023-12-03 15:14:45 -0600 Rating Details
2023-12-03 14:23:53 -0600 Rating Details
2023-12-03 13:57:40 -0600 Rating Details
2023-12-03 12:08:07 -0600 Rating Details
2023-12-03 11:37:10 -0600 Rating Details
2023-12-03 10:54:40 -0600 Rating Details
2023-12-03 10:16:56 -0600 Rating Details
2023-12-03 10:03:20 -0600 Rating Details
2023-12-03 09:57:42 -0600 Rating Details
2023-12-03 09:34:53 -0600 Rating Details
2023-12-03 09:31:29 -0600 Rating Details
2023-12-03 09:30:22 -0600 Rating Details
2023-12-03 09:26:41 -0600 Rating Details
2023-12-03 09:19:45 -0600 Rating Details
2023-12-03 09:16:59 -0600 Rating Details
2023-12-03 09:12:42 -0600 Rating Details
2023-12-03 09:09:58 -0600 Rating Details
2023-12-03 08:50:39 -0600 Rating Details
2023-12-03 08:47:09 -0600 Rating Details
2023-12-03 08:46:41 -0600 Rating Details
2023-12-03 08:45:36 -0600 Rating Details
2023-12-03 08:45:12 -0600 Rating Details
2023-12-03 08:44:12 -0600 Rating Details
2023-12-03 08:43:33 -0600 Rating Details
2023-12-03 08:42:40 -0600 Rating Details
2023-12-03 08:28:44 -0600 Rating Details
2023-12-03 08:27:47 -0600 Rating Details
2023-12-03 08:25:45 -0600 Rating Details
2023-12-04 21:05:20 -0600 Rating Details
2023-12-03 20:56:43 -0600 Rating Details
2023-12-03 11:11:33 -0600 Rating Details
2023-12-03 08:41:24 -0600 Rating Details
2023-12-08 00:12:46 -0600 Rating Details
2024-05-04 13:27:32 -0500 Rating Details